These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 36000541)

  • 1. HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma.
    Tabernero J; Shen L; Elimova E; Ku G; Liu T; Shitara K; Lin X; Boyken L; Li H; Grim J; Ajani J
    Future Oncol; 2022 Sep; 18(29):3255-3266. PubMed ID: 36000541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
    Catenacci DV; Rosales M; Chung HC; H Yoon H; Shen L; Moehler M; Kang YK
    Future Oncol; 2021 Apr; 17(10):1155-1164. PubMed ID: 33263418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
    Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
    Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
    Janjigian YY; Kawazoe A; Yañez P; Li N; Lonardi S; Kolesnik O; Barajas O; Bai Y; Shen L; Tang Y; Wyrwicz LS; Xu J; Shitara K; Qin S; Van Cutsem E; Tabernero J; Li L; Shah S; Bhagia P; Chung HC
    Nature; 2021 Dec; 600(7890):727-730. PubMed ID: 34912120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.
    Klempner SJ; Maron SB; Chase L; Lomnicki S; Wainberg ZA; Catenacci DVT
    Oncologist; 2019 Apr; 24(4):475-482. PubMed ID: 30470690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
    Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
    Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pembrolizumab with trastuzumab and chemotherapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinomas with surexpression of HER2 and CPS≥1].
    Lévêque I; Spitzer E
    Bull Cancer; 2024 Feb; 111(2):130-132. PubMed ID: 38071114
    [No Abstract]   [Full Text] [Related]  

  • 9. The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma.
    Lu Z; Yang S; Luo X; Shi Y; Lee JS; Deva S; Liu T; Chao Y; Zhang Y; Huang R; Xu Y; Shen Z; Shen L
    Gastric Cancer; 2022 Sep; 25(5):943-955. PubMed ID: 35778636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.
    Chung HC; Bang YJ; S Fuchs C; Qin SK; Satoh T; Shitara K; Tabernero J; Van Cutsem E; Alsina M; Cao ZA; Lu J; Bhagia P; Shih CS; Janjigian YY
    Future Oncol; 2021 Feb; 17(5):491-501. PubMed ID: 33167735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.
    Catenacci DVT; Kang YK; Yoon HH; Shim BY; Kim ST; Oh DY; Spira AI; Ulahannan SV; Avery EJ; Boland PM; Chao J; Chung HC; Gardner F; Klempner SJ; Lee KW; Oh SC; Peguero J; Sonbol MB; Shen L; Moehler M; Sun J; Li D; Rosales MK; Park H
    ESMO Open; 2022 Oct; 7(5):100563. PubMed ID: 36029651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
    Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
    Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer.
    Grávalos C; Gómez-Martín C; Rivera F; Alés I; Queralt B; Márquez A; Jiménez U; Alonso V; García-Carbonero R; Sastre J; Colomer R; Cortés-Funes H; Jimeno A
    Clin Transl Oncol; 2011 Mar; 13(3):179-84. PubMed ID: 21421462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
    Porth I; Hirsch D; Ceribas Y; Weidner P; Weichert W; Götze TO; Perner S; Luley K; Heyer CM; de la Torre C; Hofheinz RD; Lorenzen S; Gaiser T
    Eur J Cancer; 2023 Apr; 183():119-130. PubMed ID: 36848831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tislelizumab plus chemotherapy is an optimal option for second-line treatment for advanced gastroesophageal junction adenocarcinoma.
    Yang P; Pan T; Wang MK; Xiao MS; Zhang S; Liu S
    Anticancer Drugs; 2024 Aug; 35(7):666-671. PubMed ID: 38527277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
    Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
    BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of tislelizumab plus chemotherapy vs chemotherapy as first-line treatment of PD-L1 positive advanced gastric or gastroesophageal junction adenocarcinoma from a Chinese perspective.
    Li W; Wan L; Zhang J
    Expert Rev Gastroenterol Hepatol; 2024 Jun; 18(6):293-301. PubMed ID: 38923910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.
    Deguchi Y; Okabe H; Oshima N; Hisamori S; Minamiguchi S; Muto M; Sakai Y
    Gastric Cancer; 2017 May; 20(3):416-427. PubMed ID: 27517839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
    Bartley AN; Washington MK; Ventura CB; Ismaila N; Colasacco C; Benson AB; Carrato A; Gulley ML; Jain D; Kakar S; Mackay HJ; Streutker C; Tang L; Troxell M; Ajani JA
    Am J Clin Pathol; 2016 Dec; 146(6):647-669. PubMed ID: 28077399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
    Tabernero J; Hoff PM; Shen L; Ohtsu A; Shah MA; Cheng K; Song C; Wu H; Eng-Wong J; Kim K; Kang YK
    Lancet Oncol; 2018 Oct; 19(10):1372-1384. PubMed ID: 30217672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.